EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary†

Coadministration of Dabigatran Etexilate and Atorvastatin

(2013) Joachim Stangier et al.   American Journal of Cardiovascular Drugs

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

(2013) Wolfgang Mueck et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

“R” for “Renal” and for “Risk”

(2013) A. John Camm et al.   CIRCULATION

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

(2013) Hein Heidbuchel et al.   EUROPACE

A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice

(2013) Dana Berti et al.   EUROPEAN HEART JOURNAL

Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran

(2012) Joanne van Ryn et al.   AMERICAN JOURNAL OF MEDICINE

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding

(2012) T. E. Warkentin et al.   BLOOD

Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin

(2012) Sebastian Härtter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin

(2012) Jeff S. Healey et al.   CIRCULATION

Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation

(2012) Jonathan P. Piccini et al.   CIRCULATION

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

(2012) Antonio L. Dans et al.   CIRCULATION

Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation

(2012) Kenichi Kaseno et al.   CIRCULATION JOURNAL

A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation

(2012) Stephen Andrew LaHaye et al.   EUROPEAN HEART JOURNAL

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study

(2012) Leif Friberg et al.   EUROPEAN HEART JOURNAL

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

(2012) Stefan H. Hohnloser et al.   EUROPEAN HEART JOURNAL

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

A comparison of bleeding complications post-ablation between warfarin and dabigatran

(2012) David Snipelisky et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes

(2012) Raffaele De Caterina et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation

(2012) Dhanunjaya Lakkireddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease

(2012) Jonas Bjerring Olesen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

(2012) Raphael Marlu et al.   THROMBOSIS AND HAEMOSTASIS

Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis

(2011) Pierre Sié et al.   Archives of Cardiovascular Diseases

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

(2011) Rangadham Nagarakanti et al.   CIRCULATION

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

(2011) K. A. A. Fox et al.   EUROPEAN HEART JOURNAL

The Use of Dabigatran Immediately After Atrial Fibrillation Ablation

(2011) ROGER A. WINKLE et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban

(2011) Kenneth Todd Moore et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

(2011) M. J. Gnoth et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation

(2011) Ricarda Marinigh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

(2011) K.-H. LIESENFELD et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

(2011) John H. Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

(2011) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran

(2011) Wei Zhou et al.   STROKE

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPACE

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage

(2010) Lewis B. Morgenstern et al.   STROKE

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation

(2008) R D Lopes et al.   HEART